Revitope Enters into a License Agreement for Next-generation T Cell Engagement Technology
Hand-out
Press Releases
Revitope Oncology, Inc.  
October 29, 2024

Revitope Enters into a License Agreement for Next-generation T Cell Engagement Technology

Genmab secures rights to Revitope's proprietary, conditional T Cell Engagement (TCE) TwoGATE™ technology for conducting research against multiple drug target pairs with options for exclusive worldwide development and commercialization for

avatar profile Olean Times Herald

Olean Times Herald


Local & Social